Vote Scores

Home / Companies / Aurinia Pharmaceuticals Inc. / 3 Jun 2026

Meeting · year to 30 June 2026339 filers reporting

Aurinia Pharmaceuticals Inc.: meeting of 3 Jun 2026

Votes reported on Form N-PX, item by item

339 Form N-PX filers reported votes at the Aurinia Pharmaceuticals Inc. meeting of 3 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

5 nominees; 96.8% of reported votes for; 4 filers withheld from or voted against at least one nominee.

864 vote records from 96 filers. 2 of the 93 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

94.8% for0.0% against5.2% other2.2% against management96 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

459 vote records from 338 filers. 20 of the 317 filers that marked the item either way voted against management. 21 filers reported this item without a management mark.

87.0% for6.2% against6.8% other6.3% against management338 filers97.7% for2.3% against0.0% other1.8% against management58,058,496 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

173 vote records from 96 filers. 1 of the 93 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

95.8% for0.0% against4.2% other1.1% against management96 filers99.9% for0.0% against0.1% other0.1% against management12,705,309 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalNo reportForNo report
State Street and SPDRForForFor
American CenturyForForFor
Franklin TempletonForForFor
InvescoForAgainst *For
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsForForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForFor
J.P. MorganForForFor
Goldman SachsForForFor
WisdomTreeForForFor
PGIM and PrudentialForForFor
Northern Trust and FlexSharesForForFor
SEIForForFor
T. Rowe PriceForForFor
Lincoln FinancialForForFor
VoyaForForFor
First TrustForForFor
Russell InvestmentsSplit or no voteForSplit or no vote
NationwideForForFor
Brighthouse FundsForForFor
Guggenheim and RydexForForFor
Columbia ThreadneedleForForFor
BNY MellonNo reportForNo report
PrincipalForForFor
Pacific Life fundsForForFor
Global XForForFor
Federated HermesForForFor
AllianceBernsteinNo reportForNo report
DWSForForFor
AllspringNo reportSplit or no voteNo report
Janus HendersonForForFor
Neuberger BermanNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Aurinia Pharmaceuticals Inc. meeting?

339 Form N-PX filers reported votes at the meeting of 3 Jun 2026. On say-on-pay, 20 of 317 voted against management (6.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aurinia Pharmaceuticals Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Aurinia Pharmaceuticals Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aurinia Pharmaceuticals Inc. with a meeting date within three days of 3 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.